遺伝子・細胞治療

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Datamonitor Healthcare's Top Research Reports

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Scrip: 世界の医...

Webinar: Is Biopharma Fit For the New Decade?

Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.

Adoptive Cell Therapy

Citeline recently introduced a new Therapeutic Class called "Adoptive cell therapy", enabling more granular searching capabilities to hone in on this exciting cancer immunotherapy that is expanding the horizon of personalized medicine

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Zolgensma Data Integrity Fallout

Novartis finds itself facing possible criminal or civil action for admitted data manipulation on its application for Zolgensma, a gene therapy used to treat children with spinal muscular atrophy (SMA) – manipulation disclosed only after FDA approval. Pink Sheet was the first to report on the drug’s loss of EU accelerated assessment, nearly 3 weeks before the pharma giant admitted to submitting falsified data to FDA. Follow the scandal and anticipate its implications on the industry with Pink Sheet’s coverage and timeline.

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

オンラインセミナー：NASH治療薬の展望と市場動向

NASH（非アルコール性脂肪性肝炎）はさらに大きな流行病となりつつあり、あらゆる規模の企業が、業界初のNASH治療薬を市場に出すためにしのぎを削っています。新薬および転用された新薬探索、NASHの治療に関する詳細なディスカッション、およびこの分野のディールメイキング、ライセンスシング、提携戦略についてお聞きください。

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.